Trial · NCT07900061
Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer
NCT07900061, Phase 3, Not yet recruiting, Sir Run Run Shaw Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer. Trials, record NCT07900061. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900061
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer
- NCT number
- NCT07900061
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 210 participants, estimated
- Lead sponsor
- Sir Run Run Shaw Hospital
- Conditions
- Rectal Cancer
- Interventions
- node-sparing modified short-course radiotherapy, standard short-course radiotherapy
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease Free Survival (DFS) | up to 5 years | Time from randomization to the first occurrence of locoregional recurrence, distant metastasis, new invasive primary colorectal carcinoma or death from any cause, whichever occurs first. |
| Secondary | Complete Response (CR) rate | Up to 6 months | The complete response (CR) rate is defined as the proportion of subjects achieving a complete response including clinical complete response accepting watch and wait strategy and pathological complete response who underwent the surgery. |
| Secondary | Overall Survival (OS) | Up to 8 years | Overall survival (OS) is defined as the time interval from randomization to death from any cause. |
| Secondary | Organ Preservation Rate (OPR) | Up to 5 years | Organ preservation rate (OPR) is defined as the proportion of participants with successful organ preservation at the pre-specified time point from randomization. Organ preservation is regarded as failure if any of the following occurs: 1) performance of definitive total mesorectal excision (TME); 2) development of unresectable locoregional tumor regrowth or recurrence; 3) creation of permanent stoma. Local excision is not considered definitive radical resection. |
| Secondary | Locoregional Control Rate (LCR) | Up to 5 years | Locoregional control rate (LCR) is defined as the proportion of subjects without locoregional failure from randomization up to the prespecified time point. Locoregional failure is defined as the first documented occurrence of primary rectal tumor regrowth or pelvic regional nodal recurrence. Isolated distant metastasis alone shall not be regarded as locoregional failure. |
| Secondary | Locoregional Recurrence Free Survival (LRFS) | Up to 5 years | Locoregional recurrence free survival (LRFS) is defined as the time interval from randomization to the first documented locoregional failure. Locoregional failure is defined as the first documented occurrence of primary rectal tumor regrowth or pelvic regional nodal recurrence. |
| Secondary | Distant Metastasis-Free Survival (DMFS) | Up to 5 years | Distant metastasis free survival (DMFS) is defined as the time interval from randomization to the first documented distant metastatic event. Distant metastatic event is defined as the first documented distant metastasis outside the pelvis. |
| Secondary | Adverse Event (AE) | Up to 5 years | Any untoward medical occurrence temporally associated with study treatment, whether or not related to the study intervention. The incidence rates of adverse events will be calculated and compared between the two treatment groups. |
| Secondary | Quality of life (QoL) assessment via EORTC QLQ-C30 | Up to 5 years | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3.0. This is a validated patient-reported questionnaire for cancer patients. The scale score ranges from 0 to 100. Higher scores indicate better global health status and quality of life. |
| Secondary | Quality of life (QoL) assessment via EORTC QLQ-CR29. | Up to 5 years | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Cancer Module 29 (EORTC QLQ-CR29). The scale score ranges from 0 to 100. Higher scores indicate better body image but more severe blood and mucus in stool and more severe stoma care problems. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900061
GET https://conductscience.org/api/trials/v1/NCT07900061/registered